The effects of disease modifying anti-rheumatic drugs on osteoclastogenesis and bone destruction in rheumatoid arthritis.
Finding the means to ameliorate and prevent bone destruction as well as control inflammation is an urgent issue in the treatment of rheumatoid arthritis (RA). Recently, it has been demonstrated that osteoclastogenesis plays an important role in the bone destruction and pathogenesis of RA. Here, we review the effects of disease modifying anti-rheumatic drugs (DMRAD) on the amelioration of bone destruction and osteoclastogenesis.
Institute of Rheumatology, Tokyo Women's Medical University, Japan.
Yuki
Y
Nanke
Toru
T
Yago
Shigeru
S
Kotake
D000818:Animals; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001847:Bone Diseases / Q000517:prevention & control*; D002454:Cell Differentiation / Q000187:drug effects*; D006801:Humans; D010010:Osteoclasts / Q000187:drug effects*
D018501:Antirheumatic Agents